Overview

* Guardant Health Q2 2025 revenue rises 31%, beating analyst expectations, per LSEG data

* The precision medicine company focused on improving cancer raises 2025 revenue guidance to $915-$925 mln

Outlook

* Guardant Health ( GH ) raises 2025 revenue guidance to $915-$925 mln

* Company expects 2025 oncology revenue to grow 20% year-over-year

* Screening revenue now expected at $55-$60 mln for 2025

* Biopharma & Data revenue growth expected in mid-teens for 2025

Result Drivers

* ONCOLOGY GROWTH - Driven by 30% increase in test volume and improved reimbursement rates

* SCREENING DEMAND - Strong demand for Shield tests, contributing to revenue growth

* BIOPHARMA & DATA - Revenue growth supported by increased test volumes and higher average selling prices

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $232.10 $211.20

Revenue mln mln (21

Analysts

)

Q2 Beat -$0.44 -$0.79

Adjusted (14

EPS Analysts

)

Q2 EPS -$0.8

Q2 Beat -$55 mln -$98.60

Adjusted mln (12

Net Analysts

Income )

Q2 Beat -$51.90 -$58.10

Adjusted mln mln (15

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Guardant Health Inc ( GH ) is $60.00, about 27.8% above its July 29 closing price of $43.32

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)